Torcetrapib (BioDeep_00000834994)
代谢物信息卡片
Torcetrapib
化学式: C26H25F9N2O4 (600.1670518)
中文名称: 托彻普
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC1CC(C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C(=O)OC
InChI: InChI=1S/C26H25F9N2O4/c1-4-18-12-21(19-11-15(24(27,28)29)6-7-20(19)37(18)23(39)41-5-2)36(22(38)40-3)13-14-8-16(25(30,31)32)10-17(9-14)26(33,34)35/h6-11,18,21H,4-5,12-13H2,1-3H3/t18-,21+/m1/s1
描述信息
D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
D009676 - Noxae > D000963 - Antimetabolites
Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM[1].
同义名列表
2 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:49203
- KEGGdrug: D06195
- PubChem: 159325
- DrugBank: DB06281
- ChEMBL: CHEMBL479527
- CAS: 262350-59-4
- CAS: 262352-17-0
- medchemexpress: HY-12089
分类词条
相关代谢途径
BioCyc(0)
PlantCyc(0)
代谢反应
8 个相关的代谢反应过程信息。
Reactome(8)
- Transport of small molecules:
Oxygen + TPNH + heme ⟶ BV + CO + Fe2+ + H2O + TPN - Lipoprotein metabolism:
ATP + CHOL + H2O ⟶ ADP + CHOL + Pi - Plasma lipoprotein remodeling:
ATP + CHOL + H2O ⟶ ADP + CHOL + Pi - HDL remodeling:
ATP + CHOL + H2O ⟶ ADP + CHOL + Pi - Transport of small molecules:
Oxygen + TPNH + heme ⟶ BV + CO + Fe2+ + H2O + TPN - Lipoprotein metabolism:
ATP + CHOL + H2O ⟶ ADP + CHOL + Pi - Plasma lipoprotein remodeling:
ATP + CHOL + H2O ⟶ ADP + CHOL + Pi - HDL remodeling:
ATP + CHOL + H2O ⟶ ADP + CHOL + Pi
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Amand F Schmidt, Nicholas B Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Mika Kivimaki, Deborah A Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C Bis, Christopher J O'Donnell, Goya Wannamethee, Andrew Wong, Jackie F Price, Alun D Hughes, Tom R Gaunt, Nora Franceschini, Dennis O Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D Hingorani, Chris Finan. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.
Nature communications.
2021 09; 12(1):5640. doi:
10.1038/s41467-021-25703-3. [PMID: 34561430] - Petr Vachal, Joseph L Duffy, Louis-Charles Campeau, Rupesh P Amin, Kaushik Mitra, Beth Ann Murphy, Pengcheng P Shao, Peter J Sinclair, Feng Ye, Revathi Katipally, Zhijian Lu, Debra Ondeyka, Yi-Heng Chen, Kake Zhao, Wanying Sun, Sriram Tyagarajan, Jianming Bao, Sheng-Ping Wang, Josee Cote, Concetta Lipardi, Daniel Metzger, Dennis Leung, Georgy Hartmann, Gordon K Wollenberg, Jian Liu, Lushi Tan, Yingju Xu, Qinghao Chen, Guiquan Liu, Robert O Blaustein, Douglas G Johns. Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
Journal of medicinal chemistry.
2021 09; 64(18):13215-13258. doi:
10.1021/acs.jmedchem.1c00959. [PMID: 34375108] - Wilson Alberto Tárraga, Horacio Alberto Garda, Juan Domingo Toledo, Marina Cecilia Gonzalez. Potential Inhibitors of the Activity of the Cholesterol-Ester Transfer Protein.
Journal of computational biology : a journal of computational molecular cell biology.
2019 12; 26(12):1458-1469. doi:
10.1089/cmb.2018.0227. [PMID: 31356116] - Sneha M Dixit, Mohd Ahsan, Sanjib Senapati. Steering the Lipid Transfer To Unravel the Mechanism of Cholesteryl Ester Transfer Protein Inhibition.
Biochemistry.
2019 09; 58(36):3789-3801. doi:
10.1021/acs.biochem.9b00301. [PMID: 31418269] - Zhiwei Yang, Yang Cao, Dongxiao Hao, Xiaohui Yuan, Lei Zhang, Shengli Zhang. Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback.
Journal of biomolecular structure & dynamics.
2018 Aug; 36(10):2567-2580. doi:
10.1080/07391102.2017.1363661. [PMID: 28777919] - Stephen A Williams, Ashwin C Murthy, Robert K DeLisle, Craig Hyde, Anders Malarstig, Rachel Ostroff, Sophie J Weiss, Mark R Segal, Peter Ganz. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Circulation.
2018 03; 137(10):999-1010. doi:
10.1161/circulationaha.117.028213. [PMID: 28974520] - Benoit J Arsenault, Francine Petrides, Fatiha Tabet, Weihang Bao, G Kees Hovingh, S Matthijs Boekholdt, Stéphane Ramin-Mangata, Olivier Meilhac, David DeMicco, Kerry-Anne Rye, David D Waters, John J P Kastelein, Philip Barter, Gilles Lambert. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Journal of clinical lipidology.
2018 Jan; 12(1):130-136. doi:
10.1016/j.jacl.2017.10.001. [PMID: 29103916] - Ken Yamada, Margaret Brousseau, Wataru Honma, Akiko Iimura, Hidetomo Imase, Yuki Iwaki, Toshio Kawanami, Daniel LaSala, Guiqing Liang, Hironobu Mitani, Kazuhiko Nonomura, Osamu Ohmori, Meihui Pan, Dean F Rigel, Ichiro Umemura, Kayo Yasoshima, Guoming Zhu, Muneto Mogi. Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma.
Journal of medicinal chemistry.
2017 10; 60(20):8466-8481. doi:
10.1021/acs.jmedchem.7b00900. [PMID: 29035537] - Dongyin Chen, Xin Huang, Hongwen Zhou, Hanqiong Luo, Pengfei Wang, Yongzhi Chang, Xinyi He, Suiying Ni, Qingqing Shen, Guoshen Cao, Hongbin Sun, Xiaoan Wen, Jun Liu. Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors.
European journal of medicinal chemistry.
2017 Oct; 139(?):201-213. doi:
10.1016/j.ejmech.2017.08.012. [PMID: 28802120] - John Bagdade, Philip Barter, Carmen Quiroga, Pierre Alaupovic. Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial).
The American journal of cardiology.
2017 06; 119(11):1753-1756. doi:
10.1016/j.amjcard.2017.02.049. [PMID: 28431663] - Spencer Phillips Hey, Jessica M Franklin, Jerry Avorn, Aaron S Kesselheim. Success, Failure, and Transparency in Biomarker-Based Drug Development: A Case Study of Cholesteryl Ester Transfer Protein Inhibitors.
Circulation. Cardiovascular quality and outcomes.
2017 Jun; 10(6):. doi:
10.1161/circoutcomes.116.003121. [PMID: 28611186] - Petra Strajhar, David Tonoli, Fabienne Jeanneret, Raphaella M Imhof, Vanessa Malagnino, Melanie Patt, Denise V Kratschmar, Julien Boccard, Serge Rudaz, Alex Odermatt. Steroid profiling in H295R cells to identify chemicals potentially disrupting the production of adrenal steroids.
Toxicology.
2017 04; 381(?):51-63. doi:
10.1016/j.tox.2017.02.010. [PMID: 28235592] - T D Filippatos, E Klouras, F Barkas, M Elisaf. Cholesteryl ester transfer protein inhibitors: challenges and perspectives.
Expert review of cardiovascular therapy.
2016 Aug; 14(8):953-62. doi:
10.1080/14779072.2016.1189327. [PMID: 27171534] - Eder C R Quintão. The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?.
European journal of clinical investigation.
2016 Jun; 46(6):581-9. doi:
10.1111/eci.12626. [PMID: 26992444] - Yajun Liu, Gino M Salituro, Keun-Joong Lee, Annette Bak, Dennis H Leung. Modulating Drug Release and Enhancing the Oral Bioavailability of Torcetrapib with Solid Lipid Dispersion Formulations.
AAPS PharmSciTech.
2015 Oct; 16(5):1091-100. doi:
10.1208/s12249-015-0299-8. [PMID: 25690735] - Philip J Barter, Stephen J Nicholls, John J P Kastelein, Kerry-Anne Rye. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
Circulation.
2015 Aug; 132(5):423-32. doi:
10.1161/circulationaha.114.014025. [PMID: 26240263] - G Kees Hovingh, Kausik K Ray, S Matthijs Boekholdt. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?.
Circulation.
2015 Aug; 132(5):433-40. doi:
10.1161/circulationaha.115.014026. [PMID: 26240264] - Francisco J Rios, Karla B Neves, Aurelie Nguyen Dinh Cat, Sarah Even, Roberto Palacios, Augusto C Montezano, Rhian M Touyz. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
The Journal of pharmacology and experimental therapeutics.
2015 Apr; 353(1):27-34. doi:
10.1124/jpet.114.221002. [PMID: 25617244] - Claire L McEvoy, Natalie L Trevaskis, Glenn A Edwards, Michael E Perlman, Catherine M Ambler, Mary C Mack, Barbara Brockhurst, Christopher J H Porter. In vitro-in vivo evaluation of lipid based formulations of the CETP inhibitors CP-529,414 (torcetrapib) and CP-532,623.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
2014 Nov; 88(3):973-85. doi:
10.1016/j.ejpb.2014.08.006. [PMID: 25152213] - Nitin Verma, Vincent M Figueredo. HDL cholesterol: all hope is not lost after the torcetrapib setback--emerging therapeutic strategies on the horizon.
American journal of therapeutics.
2014 May; 21(3):222-32. doi:
10.1097/mjt.0b013e318249a1b5. [PMID: 22967983] - François Briand, Bénédicte Prunet-Marcassus, Quentin Thieblemont, Clément Costard, Elodie Muzotte, Sylvie Sordello, Thierry Sulpice. Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters.
Atherosclerosis.
2014 Apr; 233(2):359-362. doi:
10.1016/j.atherosclerosis.2014.01.028. [PMID: 24530763] - Alejandro Gugliucci. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo.
Clinica chimica acta; international journal of clinical chemistry.
2014 Feb; 429(?):38-45. doi:
10.1016/j.cca.2013.11.021. [PMID: 24280342] - Daniel J Rader, Emil M deGoma. Future of cholesteryl ester transfer protein inhibitors.
Annual review of medicine.
2014; 65(?):385-403. doi:
10.1146/annurev-med-050311-163305. [PMID: 24422575] - Hyun Joon Shin, Peter A McCullough. Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
Nephron. Clinical practice.
2014; 127(1-4):158-64. doi:
10.1159/000363552. [PMID: 25343842] - Georges Khoueiry, Mokhtar Abdallah, Faisal Saiful, Nidal Abi Rafeh, Muhammad Raza, Tariq Bhat, Suzanne El-Sayegh, Kamyar Kalantar-Zadeh, James Lafferty. High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.
International urology and nephrology.
2014 Jan; 46(1):27-39. doi:
10.1007/s11255-012-0366-y. [PMID: 23443874] - Amir Hooshang Mohammadpour, Fatemeh Akhlaghi. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Clinical pharmacokinetics.
2013 Aug; 52(8):615-26. doi:
10.1007/s40262-013-0071-8. [PMID: 23658137] - Ernst J Schaefer. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?.
Current opinion in lipidology.
2013 Jun; 24(3):259-64. doi:
10.1097/mol.0b013e3283612454. [PMID: 23652567] - François Briand, Quentin Thieblemont, Elodie Muzotte, Thierry Sulpice. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
Arteriosclerosis, thrombosis, and vascular biology.
2013 Jan; 33(1):13-23. doi:
10.1161/atvbaha.112.252932. [PMID: 23139291] - Chuanwei Li, Wen Zhang, Faying Zhou, Caiyu Chen, Liang Zhou, Yafei Li, Ling Liu, Fang Pei, Hao Luo, Zhangxue Hu, Jing Cai, Chunyu Zeng. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.
PloS one.
2013; 8(10):e77049. doi:
10.1371/journal.pone.0077049. [PMID: 24204732] - Trine Holm Johannsen, Ruth Frikke-Schmidt, Jesper Schou, Børge G Nordestgaard, Anne Tybjærg-Hansen. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.
Journal of the American College of Cardiology.
2012 Nov; 60(20):2041-8. doi:
10.1016/j.jacc.2012.07.045. [PMID: 23083790] - Philip J Barter, Kerry-Anne Rye, Mohan S Beltangady, William C Ports, William T Duggan, S Matthijs Boekholdt, David A DeMicco, John J P Kastelein, Charles L Shear. Relationship between atorvastatin dose and the harm caused by torcetrapib.
Journal of lipid research.
2012 Nov; 53(11):2436-42. doi:
10.1194/jlr.p026328. [PMID: 22941786] - Shenping Liu, Anil Mistry, Jennifer M Reynolds, David B Lloyd, Matthew C Griffor, David A Perry, Roger B Ruggeri, Ronald W Clark, Xiayang Qiu. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors.
The Journal of biological chemistry.
2012 Oct; 287(44):37321-9. doi:
10.1074/jbc.m112.380063. [PMID: 22961980] - Philip J Barter, Kerry-Anne Rye. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.
Journal of lipid research.
2012 Sep; 53(9):1755-66. doi:
10.1194/jlr.r024075. [PMID: 22550134] - Michael H Davidson. HDL and CETP Inhibition: Will This DEFINE the Future?.
Current treatment options in cardiovascular medicine.
2012 Aug; 14(4):384-90. doi:
10.1007/s11936-012-0191-8. [PMID: 22723175] - Bernd Hewing, Edward A Fisher. Rationale for cholesteryl ester transfer protein inhibition.
Current opinion in lipidology.
2012 Aug; 23(4):372-6. doi:
10.1097/mol.0b013e328353ef1d. [PMID: 22517614] - Stephen J Nicholls. Evacetrapib.
Current cardiology reports.
2012 Jun; 14(3):245-50. doi:
10.1007/s11886-012-0252-3. [PMID: 22362199] - Margaret R Diffenderfer, Margaret E Brousseau, John S Millar, P Hugh R Barrett, Chorthip Nartsupha, Peter M Schaefer, Megan L Wolfe, Gregory G Dolnikowski, Daniel J Rader, Ernst J Schaefer. Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.
Journal of lipid research.
2012 Jun; 53(6):1190-9. doi:
10.1194/jlr.m019570. [PMID: 22474066] - Maria-Carmen Fernandez, Ana Escribano, Ana I Mateo, Saravanan Parthasarathy, Eva M Martin de la Nava, Xiaodong Wang, Sandra L Cockerham, Thomas P Beyer, Robert J Schmidt, Guoqing Cao, Youyan Zhang, Timothy M Jones, Anthony Borel, Stephanie A Sweetana, Ellen A Cannady, Gregory Stephenson, Scott Frank, Nathan B Mantlo. Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
Bioorganic & medicinal chemistry letters.
2012 May; 22(9):3056-62. doi:
10.1016/j.bmcl.2012.03.075. [PMID: 22497761] - Ryan M Fryer, Paul C Harrison, Akalushi Muthukumarana, Suzanne G Nodop Mazurek, Khing Jow Ng, Rong Rhonda Chen, Kyle E Harrington, Roger M Dinallo, Liguo Chi, Glenn A Reinhart. Strategic integration of in vivo cardiovascular models during lead optimization: predictive value of 4 models independent of species, route of administration, and influence of anesthesia.
Journal of cardiovascular pharmacology.
2012 Apr; 59(4):369-76. doi:
10.1097/fjc.0b013e31824485dd. [PMID: 22179024] - Wijtske Annema, Uwe Jf Tietge. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.
Nutrition & metabolism.
2012 Mar; 9(1):25. doi:
10.1186/1743-7075-9-25. [PMID: 22458435] - Darren K McGuire, David Aguilar. Letter by McGuire and Aguilar regarding article, 'Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial'.
Circulation.
2012 Mar; 125(9):e427. doi:
10.1161/circulationaha.111.057844. [PMID: 22392870] - F K Knop. Letter by Knop regarding article, 'Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial'.
Circulation.
2012 Mar; 125(9):e428. doi:
10.1161/circulationaha.111.060152. [PMID: 22392871] - Douglas G Johns, Joseph Duffy, Timothy Fisher, Brian K Hubbard, Michael J Forrest. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Drugs.
2012 Mar; 72(4):491-507. doi:
10.2165/11599310-000000000-00000. [PMID: 22356288] - Uchechukwu K Sampson, Sergio Fazio, MacRae F Linton. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.
Current atherosclerosis reports.
2012 Feb; 14(1):1-10. doi:
10.1007/s11883-011-0219-7. [PMID: 22102062] - Heng Wei, Chunxiu Hu, Mei Wang, Anita M van den Hoek, Theo H Reijmers, Suzan Wopereis, Jildau Bouwman, Raymond Ramaker, Henrie A A J Korthout, Marco Vennik, Thomas Hankemeier, Louis M Havekes, Renger F Witkamp, Elwin R Verheij, Guowang Xu, Jan van der Greef. Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP mice.
PloS one.
2012; 7(1):e30332. doi:
10.1371/journal.pone.0030332. [PMID: 22291936] - Hisashi Shinkai. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Vascular health and risk management.
2012; 8(?):323-31. doi:
10.2147/vhrm.s25238. [PMID: 22661899] - Nicola Martinelli, Roberta Micaglio, Letizia Consoli, Patrizia Guarini, Elisa Grison, Francesca Pizzolo, Simonetta Friso, Elisabetta Trabetti, Pier Franco Pignatti, Roberto Corrocher, Oliviero Olivieri, Domenico Girelli. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease.
Experimental diabetes research.
2012; 2012(?):231502. doi:
10.1155/2012/231502. [PMID: 21960992] - Artturi Koivuniemi, Timo Vuorela, Petri T Kovanen, Ilpo Vattulainen, Marja T Hyvönen. Lipid exchange mechanism of the cholesteryl ester transfer protein clarified by atomistic and coarse-grained simulations.
PLoS computational biology.
2012 Jan; 8(1):e1002299. doi:
10.1371/journal.pcbi.1002299. [PMID: 22253581] - Alyse S Goldberg, Robert A Hegele. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Drug design, development and therapy.
2012; 6(?):251-9. doi:
10.2147/dddt.s34976. [PMID: 23055695] - Chun-Hsu Pan, Chia-Hua Tsai, Wen-Hsin Lin, Guo-Yan Chen, Chieh-Hsi Wu. Ethanolic Extract of Vitis thunbergii Exhibits Lipid Lowering Properties via Modulation of the AMPK-ACC Pathway in Hypercholesterolemic Rabbits.
Evidence-based complementary and alternative medicine : eCAM.
2012; 2012(?):436786. doi:
10.1155/2012/436786. [PMID: 22536284] - Laurent Laforest, Baishali M Ambegaonkar, Thierry Souchet, Vasilisa Sazonov, Eric Van Ganse. Mixed dyslipidemias in primary care patients in France.
Vascular health and risk management.
2012; 8(?):247-54. doi:
10.2147/vhrm.s27668. [PMID: 22566746] - Klaus G Parhofer. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
Core evidence.
2012; 7(?):29-38. doi:
10.2147/ce.s25239. [PMID: 22701100] - Eric J Niesor, Evelyne Chaput, Andreas Staempfli, Denise Blum, Michael Derks, David Kallend. Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Atherosclerosis.
2011 Dec; 219(2):761-7. doi:
10.1016/j.atherosclerosis.2011.09.017. [PMID: 21982411] - Gregor Dernick, Stefan Obermüller, Cyrill Mangold, Christine Magg, Hugues Matile, Oliver Gutmann, Elisabeth von der Mark, Corinne Handschin, Cyrille Maugeais, Eric J Niesor. Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays.
Journal of lipid research.
2011 Dec; 52(12):2323-2331. doi:
10.1194/jlr.d016824. [PMID: 21971713] - B Sjouke, D M Kusters, J J P Kastelein, G K Hovingh. Familial hypercholesterolemia: present and future management.
Current cardiology reports.
2011 Dec; 13(6):527-36. doi:
10.1007/s11886-011-0219-9. [PMID: 21938413] - Guoqing Cao, Thomas P Beyer, Youyan Zhang, Robert J Schmidt, Yan Q Chen, Sandra L Cockerham, Karen M Zimmerman, Sotirios K Karathanasis, Ellen A Cannady, Todd Fields, Nathan B Mantlo. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.
Journal of lipid research.
2011 Dec; 52(12):2169-2176. doi:
10.1194/jlr.m018069. [PMID: 21957197] - Philip Barter, Kerry-Anne Rye. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?.
Trends in pharmacological sciences.
2011 Dec; 32(12):694-9. doi:
10.1016/j.tips.2011.07.004. [PMID: 22088767] - Peter P Toth. CETP Inhibition: does the future look promising?.
Current cardiology reports.
2011 Dec; 13(6):559-65. doi:
10.1007/s11886-011-0218-x. [PMID: 21909703] - Paul J W H Kappelle, Arie van Tol, Bruce H R Wolffenbuttel, Robin P F Dullaart. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Cardiovascular therapeutics.
2011 Dec; 29(6):e89-99. doi:
10.1111/j.1755-5922.2010.00201.x. [PMID: 20645987] - Suk Min Seo, Eun-Ho Choo, Yoon-Seok Koh, Mahn Won Park, Dong Il Shin, Yoon Seok Choi, Hun-Jun Park, Dong Bin Kim, Sung Ho Her, Jong Min Lee, Chul Soo Park, Pum-Joon Kim, Keon Woong Moon, Kiyuk Chang, Hee Yeol Kim, Ki Dong Yoo, Doo Soo Jeon, Wook Sung Chung, Yong Gyu Park, Ki-Bae Seung. High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention.
Heart (British Cardiac Society).
2011 Dec; 97(23):1943-50. doi:
10.1136/hrt.2011.225466. [PMID: 21665885] - Jian-Kai Zhong, Zhi-Gang Guo, Chen Li, Zhen-Kun Wang, Wen-Yan Lai, Yan Tu. Probucol alleviates atherosclerosis and improves high density lipoprotein function.
Lipids in health and disease.
2011 Nov; 10(?):210. doi:
10.1186/1476-511x-10-210. [PMID: 22078494] - Cesare R Sirtori. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Expert opinion on investigational drugs.
2011 Nov; 20(11):1543-54. doi:
10.1517/13543784.2011.614946. [PMID: 21961529] - Kristina Duwensee, Stefan Schwaiger, Ivan Tancevski, Kathrin Eller, Miranda van Eck, Patrick Markt, Tobias Linder, Ursula Stanzl, Andreas Ritsch, Josef R Patsch, Daniela Schuster, Hermann Stuppner, David Bernhard, Philipp Eller. Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein.
Atherosclerosis.
2011 Nov; 219(1):109-15. doi:
10.1016/j.atherosclerosis.2011.07.023. [PMID: 21820657] - Santiago Redondo, José Martínez-González, Concha Urraca, Teresa Tejerina. Emerging therapeutic strategies to enhance HDL function.
Lipids in health and disease.
2011 Oct; 10(?):175. doi:
10.1186/1476-511x-10-175. [PMID: 21985435] - Philip J Barter, Kerry-Anne Rye, Jean-Claude Tardif, David D Waters, S Matthijs Boekholdt, Andrei Breazna, John J P Kastelein. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Circulation.
2011 Aug; 124(5):555-62. doi:
10.1161/circulationaha.111.018259. [PMID: 21804130] - Eric J Niesor. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Current opinion in lipidology.
2011 Aug; 22(4):288-95. doi:
10.1097/mol.0b013e3283475e00. [PMID: 21587074] - Johannes Hm Levels, Pierre Geurts, Helen Karlsson, Raphaël Marée, Stefan Ljunggren, Louise Fornander, Louis Wehenkel, Mats Lindahl, Erik Sg Stroes, Jan A Kuivenhoven, Joost Cm Meijers. High-density lipoprotein proteome dynamics in human endotoxemia.
Proteome science.
2011 Jun; 9(1):34. doi:
10.1186/1477-5956-9-34. [PMID: 21711511] - M John Chapman, Henry N Ginsberg, Pierre Amarenco, Felicita Andreotti, Jan Borén, Alberico L Catapano, Olivier S Descamps, Edward Fisher, Petri T Kovanen, Jan Albert Kuivenhoven, Philippe Lesnik, Luis Masana, Børge G Nordestgaard, Kausik K Ray, Zeljko Reiner, Marja-Riitta Taskinen, Lale Tokgözoglu, Anne Tybjærg-Hansen, Gerald F Watts. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
European heart journal.
2011 Jun; 32(11):1345-61. doi:
10.1093/eurheartj/ehr112. [PMID: 21531743] - Antonio Arteaga, Attilio Rigotti. [Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: second act 'A rebirth of hope'].
Revista medica de Chile.
2011 Jun; 139(6):802-6. doi:
/s0034-98872011000600016. [PMID: 22051763] - Raphaël Duivenvoorden, Zahi A Fayad. Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies.
Current atherosclerosis reports.
2011 Jun; 13(3):277-84. doi:
10.1007/s11883-011-0176-1. [PMID: 21465111] - Eliane S Parra, Aline Urban, Natalia B Panzoldo, Rui T Nakamura, Rogério Oliveira, Eliana C de Faria. A reduction of CETP activity, not an increase, is associated with modestly impaired postprandial lipemia and increased HDL-cholesterol in adult asymptomatic women.
Lipids in health and disease.
2011 May; 10(?):87. doi:
10.1186/1476-511x-10-87. [PMID: 21609439] - Guohua Song, Jia Liu, Zhenmei Zhao, Yang Yu, Hua Tian, Shutong Yao, Guoli Li, Shucun Qin. Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet.
Lipids in health and disease.
2011 Jan; 10(?):8. doi:
10.1186/1476-511x-10-8. [PMID: 21241519] - Young-Guk Ko, Byeong-Keuk Kim, Byoung Kwon Lee, Woong Chol Kang, Seung Hyuk Choi, Sang Wook Kim, Jong Ho Lee, Myoungsook Lee, Yasuhiro Honda, Peter J Fitzerald, Won-Heum Shim. Study design and rationale of 'Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)' study: a double-blind randomised controlled multicenter clinical trial.
Trials.
2011 Jan; 12(?):10. doi:
10.1186/1745-6215-12-10. [PMID: 21226953] - Janine Pöss, Florian Custodis, Christian Werner, Oliver Weingärtner, Michael Böhm, Ulrich Laufs. Cardiovascular disease and dyslipidemia: beyond LDL.
Current pharmaceutical design.
2011; 17(9):861-70. doi:
10.2174/138161211795428858. [PMID: 21418031] - Marta A Miyares. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
The Annals of pharmacotherapy.
2011 Jan; 45(1):84-94. doi:
10.1345/aph.1p446. [PMID: 21205945] - Richard Kones. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
Drug design, development and therapy.
2011; 5(?):325-80. doi:
10.2147/dddt.s14934. [PMID: 21792295] - Krishnaswami Vijayaraghavan. Treatment of dyslipidemia in patients with type 2 diabetes.
Lipids in health and disease.
2010 Dec; 9(?):144. doi:
10.1186/1476-511x-9-144. [PMID: 21172030] - Eric J Niesor, Christine Magg, Naoto Ogawa, Hiroshi Okamoto, Elisabeth von der Mark, Hugues Matile, Georg Schmid, Roger G Clerc, Evelyne Chaput, Denise Blum-Kaelin, Walter Huber, Ralf Thoma, Philippe Pflieger, Makoto Kakutani, Daisuke Takahashi, Gregor Dernick, Cyrille Maugeais. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Journal of lipid research.
2010 Dec; 51(12):3443-54. doi:
10.1194/jlr.m008706. [PMID: 20861162] - Camila Canteiro Leança, Marisa Passarelli, Edna R Nakandakare, Eder C R Quintão. [HDL: the yin-yang of cardiovascular disease].
Arquivos brasileiros de endocrinologia e metabologia.
2010 Dec; 54(9):777-84. doi:
10.1590/s0004-27302010000900002. [PMID: 21340169] - Robert Guthrie. Niacin or ezetimibe for patients with, or at risk of coronary heart disease.
Clinical Medicine Insights. Cardiology.
2010 Oct; 4(?):99-110. doi:
10.4137/cmc.s5970. [PMID: 21079754] - Tetsuro Miyazaki, Kazunori Shimada, Katsumi Miyauchi, Atsumi Kume, Kosei Tanimoto, Takashi Kiyanagi, Katsuhiko Sumiyoshi, Makoto Hiki, Hiroshi Mokuno, Shinya Okazaki, Hitoshi Sato, Takeshi Kurata, Hiroyuki Daida. Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting.
Lipids in health and disease.
2010 Oct; 9(?):122. doi:
10.1186/1476-511x-9-122. [PMID: 20973966] - Roger L Chang, Li Xie, Lei Xie, Philip E Bourne, Bernhard Ø Palsson. Drug off-target effects predicted using structural analysis in the context of a metabolic network model.
PLoS computational biology.
2010 Sep; 6(9):e1000938. doi:
10.1371/journal.pcbi.1000938. [PMID: 20957118] - Mollie Ranalletta, Kathleen K Bierilo, Ying Chen, Denise Milot, Qing Chen, Elaine Tung, Caroline Houde, Nadine H Elowe, Margarita Garcia-Calvo, Gene Porter, Suzanne Eveland, Betsy Frantz-Wattley, Mike Kavana, George Addona, Peter Sinclair, Carl Sparrow, Edward A O'Neill, Ken S Koblan, Ayesha Sitlani, Brian Hubbard, Timothy S Fisher. Biochemical characterization of cholesteryl ester transfer protein inhibitors.
Journal of lipid research.
2010 Sep; 51(9):2739-52. doi:
10.1194/jlr.m007468. [PMID: 20458119] - Olaf Weber, Hilmar Bischoff, Carsten Schmeck, Michael-Friedrich Böttcher. Cholesteryl ester transfer protein and its inhibition.
Cellular and molecular life sciences : CMLS.
2010 Sep; 67(18):3139-49. doi:
10.1007/s00018-010-0418-3. [PMID: 20556633] - Smita Negi, Christie M Ballantyne. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
Journal of clinical lipidology.
2010 Sep; 4(5):365-70. doi:
10.1016/j.jacl.2010.08.008. [PMID: 21122680] - Michael H Davidson. Update on CETP inhibition.
Journal of clinical lipidology.
2010 Sep; 4(5):394-8. doi:
10.1016/j.jacl.2010.08.003. [PMID: 21122682] - Danny J Eapen, Girish L Kalra, Luay Rifai, Christina A Eapen, Nadya Merchant, Bobby V Khan. Raising HDL cholesterol in women.
International journal of women's health.
2010 Aug; 1(?):181-91. doi:
10.2147/ijwh.s5110. [PMID: 21072287] - Kunal N Bhatt, Bryan J Wells, Laurence S Sperling, Jefferson T Baer. High-density lipoprotein therapy: is there hope?.
Current treatment options in cardiovascular medicine.
2010 Aug; 12(4):315-28. doi:
10.1007/s11936-010-0081-x. [PMID: 20842556] - M E Kleber, T B Grammer, W März. [High-density lipoprotein (HDL) and cholesteryl ester transfer protein (CETP): role in lipid metabolism and clinical meaning].
MMW Fortschritte der Medizin.
2010 Jul; 152 Suppl 2(?):47-55. doi:
NULL. [PMID: 21591319] - Zhu Chen, Marina Ichetovkin, Marc Kurtz, Emanuel Zycband, Douglas Kawka, John Woods, Xuanmin He, Andrew S Plump, Eric Hailman. Cholesterol in human atherosclerotic plaque is a marker for underlying disease state and plaque vulnerability.
Lipids in health and disease.
2010 Jun; 9(?):61. doi:
10.1186/1476-511x-9-61. [PMID: 20540749] - Michael K Hansen, Matthew J McVey, Ray F White, Jeffrey J Legos, Jean-Marie Brusq, Didier A Grillot, Marc Issandou, Frank C Barone. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
Journal of cardiovascular pharmacology and therapeutics.
2010 Jun; 15(2):196-202. doi:
10.1177/1074248410362891. [PMID: 20332533] - Jennifer G Robinson. Dalcetrapib: a review of Phase II data.
Expert opinion on investigational drugs.
2010 Jun; 19(6):795-805. doi:
10.1517/13543784.2010.488219. [PMID: 20465364] - Ronald W Clark, David Cunningham, Yang Cong, Timothy A Subashi, George T Tkalcevic, David B Lloyd, James G Boyd, Boris A Chrunyk, George A Karam, Xiayang Qiu, Ing-Kae Wang, Omar L Francone. Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection.
Journal of lipid research.
2010 May; 51(5):967-74. doi:
10.1194/jlr.m002295. [PMID: 19965592] - Yun Lin, Shaymaa S Mousa, Nabil Elshourbagy, Shaker A Mousa. Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.
Vascular health and risk management.
2010 Mar; 6(?):73-85. doi:
10.2147/vhrm.s8725. [PMID: 20234782] - Arnold von Eckardstein. Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?.
Expert review of cardiovascular therapy.
2010 Mar; 8(3):345-58. doi:
10.1586/erc.10.6. [PMID: 20222814] - J Pöss, M Böhm, U Laufs. [HDL and CETP in atherogenesis].
Deutsche medizinische Wochenschrift (1946).
2010 Feb; 135(5):188-92. doi:
10.1055/s-0030-1247862. [PMID: 20082258] - Evan A Stein, Eli M Roth, James M Rhyne, Tracy Burgess, David Kallend, Jennifer G Robinson. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
European heart journal.
2010 Feb; 31(4):480-8. doi:
10.1093/eurheartj/ehp601. [PMID: 20097702] - Reecha Sofat, Aroon D Hingorani, Liam Smeeth, Steve E Humphries, Philippa J Talmud, Jackie Cooper, Tina Shah, Manjinder S Sandhu, Sally L Ricketts, S Matthijs Boekholdt, Nicholas Wareham, Kay Tee Khaw, Meena Kumari, Mika Kivimaki, Michael Marmot, Folkert W Asselbergs, Pim van der Harst, Robin P F Dullaart, Gerjan Navis, Dirk J van Veldhuisen, Wiek H Van Gilst, John F Thompson, Pamela McCaskie, Lyle J Palmer, Marcello Arca, Fabiana Quagliarini, Carlo Gaudio, François Cambien, Viviane Nicaud, Odette Poirer, Vilmundur Gudnason, Aaron Isaacs, Jacqueline C M Witteman, Cornelia M van Duijn, Michael Pencina, Ramachandran S Vasan, Ralph B D'Agostino, Jose Ordovas, Tricia Y Li, Sakari Kakko, Heikki Kauma, Markku J Savolainen, Y Antero Kesäniemi, Anton Sandhofer, Bernhard Paulweber, Jose V Sorli, Akimoto Goto, Shinji Yokoyama, Kenji Okumura, Benjamin D Horne, Chris Packard, Dilys Freeman, Ian Ford, Naveed Sattar, Valerie McCormack, Debbie A Lawlor, Shah Ebrahim, George Davey Smith, John J P Kastelein, John Deanfield, Juan P Casas. Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
Circulation.
2010 Jan; 121(1):52-62. doi:
10.1161/circulationaha.109.865444. [PMID: 20026784] - M John Chapman, Wilfried Le Goff, Maryse Guerin, Anatol Kontush. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
European heart journal.
2010 Jan; 31(2):149-64. doi:
10.1093/eurheartj/ehp399. [PMID: 19825813]